ID   UWB1.289
AC   CVCL_B079
SY   UWB1-289; UWB1289
DR   BTO; BTO:0006253
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2945
DR   BioGRID_ORCS_Cell_line; 1041
DR   BioSample; SAMN03471702
DR   cancercelllines; CVCL_B079
DR   Cell_Model_Passport; SIDM00815
DR   Cosmic-CLP; 1480374
DR   DepMap; ACH-001418
DR   EGA; EGAS00001000978
DR   GDSC; 1480374
DR   GEO; GSM711714
DR   GEO; GSM1291155
DR   GEO; GSM1670568
DR   Lonza; 1665
DR   PharmacoDB; UWB1_289_1650_2019
DR   PRIDE; PXD006939
DR   PRIDE; PXD030304
DR   Wikidata; Q54992390
RX   PubMed=17259345;
RX   PubMed=25230021;
RX   PubMed=27397505;
RX   PubMed=29242379;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 15.3 hours (PubMed=17259345); ~53 hours (ATCC=CRL-2945).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1100; BRCA1; Zygosity=Heterozygous (PubMed=17259345).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Asp825Glufs*21 (c.2475delC); ClinVar=VCV000037472; Zygosity=Heterozygous (PubMed=17259345).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.18%; Native American=0%; East Asian, North=0.95%; East Asian, South=0%; South Asian=1.35%; European, North=70.57%; European, South=26.96% (PubMed=30894373).
ST   Source(s): ATCC; Cosmic-CLP; DepMap; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9
ST   D16S539: 12
ST   D18S51: 19
ST   D21S11: 28,31
ST   D3S1358: 14,15
ST   D5S818: 13
ST   D7S820: 7,10
ST   D8S1179: 11,12 (DepMap)
ST   D8S1179: 12 (PubMed=25230021)
ST   FGA: 22
ST   Penta D: 10
ST   Penta E: 8
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 16,19
DI   NCIt; C36100; BRCA1-associated hereditary breast and ovarian cancer syndrome
DI   ORDO; Orphanet_145; Hereditary breast and ovarian cancer syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 28
//
RX   PubMed=17259345; DOI=10.1158/1541-7786.MCR-06-0234;
RA   DelloRusso C., Welcsh P.L., Wang W.-X., Garcia R.L., King M.-C.,
RA   Swisher E.M.;
RT   "Functional characterization of a novel BRCA1-null ovarian cancer cell
RT   line in response to ionizing radiation.";
RL   Mol. Cancer Res. 5:35-45(2007).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29242379; DOI=10.1074/mcp.TIR117.000383;
RA   Chong C., Marino F., Pak H., Racle J., Daniel R.T., Muller M.,
RA   Gfeller D., Coukos G., Bassani-Sternberg M.;
RT   "High-throughput and sensitive immunopeptidomics platform reveals
RT   profound interferon gamma-mediated remodeling of the human leukocyte
RT   antigen (HLA) ligandome.";
RL   Mol. Cell. Proteomics 17:533-548(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//